v3.26.3
Income Taxes (Tables) - Chemomab Therapeutics Ltd [Member]
12 Months Ended
Dec. 31, 2025
Schedule of Deferred Taxes

 

   December 31,   December 31, 
   2025   2024 
   USD thousands   USD thousands 
Net operating loss carryforward   44,464    *40,755 
Capital losses   3,271    - 
Share-based compensation expense   374    351 
Capitalized research and development costs   1,742    3,103 
Other   8    10 
Deferred tax assets   49,859    44,219 
Less - valuation allowance   (49,859)   (44,219)
           
Net deferred tax assets, net of valuation allowance   -    - 

 

*This excludes capital losses of approximately $14,223 thousands for which the Company has recorded a full valuation allowance.
Schedule of Roll forward of Valuation Allowance

 

   USD thousands 
Balance at December 31, 2022  $41,195 
Currency translation Income   (3,295)
Increase in valuation allowance   5,571 
Balance at December 31, 2023  $43,471 
Currency translation Income   (2,459)
Increase in valuation allowance   3,207 
Balance at December 31, 2024   44,219 
Increase in valuation allowance for capital losses   3,271 
Increase in valuation allowance   2,916 
Decrease in valuation allowance   (547)
Net increase during the year   5,640 
Balance at December 31, 2025   49,859 
Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense

A reconciliation of the Company’s theoretical income tax expense at the Israeli statutory income tax rate, the income tax rate in our country of tax domicile, to actual income tax expense is as follows:

 

   2025 Amount   % 
Israeli statutory income tax rate   (2,069)   23.0%
Nontaxable income or nondeductible expenses:          
Share-based compensation   120    (1.3)%
Other   5    (0.1)%
Change in valuation allowance   2,297    (25.5)%
Other   (344)   3.8%
           
Foreign tax effects   (9)   0.1%
           
Actual income tax expenses   -    0.0%

 

   December 31,   December 31, 
   2024   2023 
   USD thousands   USD thousands 
         
Loss before income taxes   (13,945)   (24,221)
Statutory tax rate   23%   23%
Theoretical tax benefit   (3,207)   (5,571)
           
Change in temporary differences for which deferred taxes were not recognized   858    (1,177)
Tax rate differential   9    10 
Non-deductible expenses   148    346 
Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards   2,192    6,392 
Actual income tax expense (Benefit)   -    - 
Schedule of Income (Loss) Before Income Taxes by Jurisdiction

 

   2025   2024   2023 
   USD thousands   USD thousands   USD thousands 
Israel   (9,035)   (13,925)   (23,534)
Foreign   40    (20)   (687)
                
Total   (8,995)   (13,945)   (24,221)